BIOMAT Database Logo BIOMAT Database Logo

Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients. 1994

M Satoh, and M Kuwana, and T Ogasawara, and A K Ajmani, and J J Langdon, and D Kimpel, and J Wang, and W H Reeves
Department of Medicine, Thurston Arthritis Research Center, University of North Carolina, Chapel Hill 27599.

Autoantibodies to RNA polymerases (RNAP) I and III are highly specific for scleroderma (SSc), whereas autoantibodies to RNAP II are associated with systemic lupus erythematosus (SLE) and overlap syndromes, as well as SSc. The specificities of autoantibodies to RNAP I, II, and III in 129 SSc sera were investigated in the present study. Immunoprecipitation and pulse-chase analysis demonstrated several patterns of autoantibody recognition of RNAPs. Some sera immunoprecipitated RNAP II only after its largest subunit was phosphorylated, suggesting that they contained autoantibodies that recognized an epitope carrying a phosphoamino acid. Autoantibody recognition of all three classes of RNAPs was influenced strongly by race. Although in SLE, autoantibodies to the phosphorylated form of RNAP II (RNAP IIO) were identified in all races, in SSc, these autoantibodies were seen in 21% of Japanese and 5% of Black patients, but never in Caucasians. A striking association of anti-RNAP IIO with anti-topoisomerase I (topo I) autoantibodies was found in Japanese and Black SSc, but not SLE, patients. However, anti-topo I Abs were not associated with anti-RNAP IIO in Caucasians. Japanese SSc patients who were positive for both anti-RNAP IIO and anti-topo I Abs had a significantly higher frequency of diffuse disease, pigmentation changes, flexion contractures, and acro-osteolysis than patients having autoantibodies to topo I alone, and were diagnosed at a younger age (p < 0.05). These data suggest that genetic factors (possibly HLA-linked) influence autoantibody specificity, and that different autoantibody fine specificities may either cause, or be predictive of, different clinical outcomes.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011233 Precipitin Tests Serologic tests in which a positive reaction manifested by visible CHEMICAL PRECIPITATION occurs when a soluble ANTIGEN reacts with its precipitins, i.e., ANTIBODIES that can form a precipitate. Precipitin Test,Test, Precipitin,Tests, Precipitin
D004264 DNA Topoisomerases, Type I DNA TOPOISOMERASES that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. DNA Topoisomerases, Type I enzymes reduce the topological stress in the DNA structure by relaxing the superhelical turns and knotted rings in the DNA helix. DNA Nicking-Closing Protein,DNA Relaxing Enzyme,DNA Relaxing Protein,DNA Topoisomerase,DNA Topoisomerase I,DNA Topoisomerase III,DNA Topoisomerase III alpha,DNA Topoisomerase III beta,DNA Untwisting Enzyme,DNA Untwisting Protein,TOP3 Topoisomerase,TOP3alpha,TOPO IIIalpha,Topo III,Topoisomerase III,Topoisomerase III beta,Topoisomerase IIIalpha,Topoisomerase IIIbeta,DNA Nicking-Closing Proteins,DNA Relaxing Enzymes,DNA Type 1 Topoisomerase,DNA Untwisting Enzymes,DNA Untwisting Proteins,Topoisomerase I,Type I DNA Topoisomerase,III beta, Topoisomerase,III, DNA Topoisomerase,III, Topo,III, Topoisomerase,IIIalpha, TOPO,IIIalpha, Topoisomerase,IIIbeta, Topoisomerase,Topoisomerase III, DNA,Topoisomerase, TOP3,beta, Topoisomerase III
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M Satoh, and M Kuwana, and T Ogasawara, and A K Ajmani, and J J Langdon, and D Kimpel, and J Wang, and W H Reeves
Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera.
November 1994, The Journal of clinical investigation,
M Satoh, and M Kuwana, and T Ogasawara, and A K Ajmani, and J J Langdon, and D Kimpel, and J Wang, and W H Reeves
Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma.
February 2014, Arthritis research & therapy,
M Satoh, and M Kuwana, and T Ogasawara, and A K Ajmani, and J J Langdon, and D Kimpel, and J Wang, and W H Reeves
Autoantibodies against RNA polymerase I in scleroderma and Sjögren's syndrome sera.
May 1987, Biochemical and biophysical research communications,
M Satoh, and M Kuwana, and T Ogasawara, and A K Ajmani, and J J Langdon, and D Kimpel, and J Wang, and W H Reeves
Identification of autoantibodies to RNA polymerase II. Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III.
June 1993, The Journal of clinical investigation,
M Satoh, and M Kuwana, and T Ogasawara, and A K Ajmani, and J J Langdon, and D Kimpel, and J Wang, and W H Reeves
[IIa/IIo conversion of RNA polymerase II during heat shock].
January 1991, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie,
M Satoh, and M Kuwana, and T Ogasawara, and A K Ajmani, and J J Langdon, and D Kimpel, and J Wang, and W H Reeves
RNA contacts subunits IIo and IIc in HeLa RNA polymerase II transcription complexes.
October 1986, The Journal of biological chemistry,
M Satoh, and M Kuwana, and T Ogasawara, and A K Ajmani, and J J Langdon, and D Kimpel, and J Wang, and W H Reeves
High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients.
February 1986, Science (New York, N.Y.),
M Satoh, and M Kuwana, and T Ogasawara, and A K Ajmani, and J J Langdon, and D Kimpel, and J Wang, and W H Reeves
Hyperphosphorylation of RNA polymerase II in response to topoisomerase I cleavage complexes and its association with transcription- and BRCA1-dependent degradation of topoisomerase I.
September 2008, Journal of molecular biology,
M Satoh, and M Kuwana, and T Ogasawara, and A K Ajmani, and J J Langdon, and D Kimpel, and J Wang, and W H Reeves
An antigenic region of topoisomerase I in DNA polymerase chain reaction-generated fragments recognized by autoantibodies of scleroderma patients.
January 1991, Molecular immunology,
M Satoh, and M Kuwana, and T Ogasawara, and A K Ajmani, and J J Langdon, and D Kimpel, and J Wang, and W H Reeves
Autoantibody to RNA polymerase I in scleroderma sera.
January 1987, The Journal of clinical investigation,
Copied contents to your clipboard!